Besides, inhibition of CLK2 was proposed to be a potential therapeutic strategy in Phelan-McDermid syndrome (PMDS) by improving autism and neuronal functions.63 The loss of ubiquitination modulation of CLK2 expression in Shank3-deficient neurons is a genetic hallmark of PMDS. This evidence concerns the gene CLK2 and Monosomy 22q13.